KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma;Vyšetření mutačního statutu genu KRAS jako součást algoritmu léčby metastatického kolorektálního karcinomu

Casopis Lekaru Ceskych

Volumn 150, Issue 6, 2011, Pages 321-326

  Dubská, Lenka ^a   Vyskočilová, Martina ^a   Nenutil, Rudolf ^a   Valík, Dalibor ^a   Knoflíčková, Dana ^a   Fabian, Pavel ^a   Kocáková, Ilona ^a   Demlová, Regina ^a   Beránek, Martin ^b   Drastíková, Monika ^b   Vošmiková, Hana ^b   Bóday, Arpád ^a   Horká, Kateřina ^a   Šímová, Jarmila ^c   Drábek, Jiří ^d   Ehrmann, Jiří Ml ^d   Hajdúch, Marián ^d   Matějčková, Milada ^e   Šíma, Radek ^f   Tvrdík, Daniel ^b   Povýšil, Ctibor ^b   Ryška, Aleš ^b   more..

^a Masarykův Onkologický Ústav ^*  (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CGB Laborato As   (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

^e FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^f BIOPTICAL LABORATORY   (Czech Republic)

Author keywords

Anti EGFR therapy; Colorectal carcinoma; K ras; Predictive molecular oncology; Standardization of diagnostic procedure; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; MONOCLONAL ANTIBODY; PANITUMUMAB;

COLORECTAL TUMOR; GENETICS; HUMAN; METASTASIS; MUTATION; ONCOGENE RAS; PATHOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MUTATION;

EID: 79960265379     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Jasperson KW, et al. Hereditary and familial colon cancer. Gastroenterology 2010; 138: 2044-2058.
2. Vogelstein B, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319(9): 525-532.
3. Malumbres M, Barbacid M. RAS oncogenes: the řrst 30 years. Nat Rev Cancer 2003; 3(6): 459-465.
4. Carta C, et al. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 2006; 79(1): 129-135. (Pubitemid 43927383)
5. Karnoub AE,Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9(7): 517-531. (Pubitemid 351881844)
6. Bernards A, Settleman J. GEFs in growth factor signaling. Growth Factors 2007; 25(5): 355-361. (Pubitemid 351194034)
7. Scheffzek K, et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997; 277(5324): 333-338. (Pubitemid 27450699)
8. Krengel U, et al. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell 1990; 62(3): 539-548.
9. Ahmadian MR, et al. Conřrmation of the arginine-řnger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras. Nat Struct Biol 1997; 4(9): 686-689.
10. Moroni M, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6(5): 279-286. (Pubitemid 40590264)
11. Saltz LB, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22(7): 1201-1208. (Pubitemid 41079832)
12. Italiano A, et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008; 15(2): 649-654.
13. Chung KY, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23(9): 1803-1810. (Pubitemid 46211358)
14. Bokemeyer C, et al. KRAS status and efřcacy of řrst-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience (abstract 4000). J Clin Oncol 2008; 26: 4000.
15. Van Cutsem E, et al. KRAS status and efřcacy in the řrst-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience (abstract 2). J Clin Oncol 2008; 26: 2.
16. Lievre A, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66(8): 3992-3995.
17. Lievre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26(3): 374-379. (Pubitemid 351171687)
18. Di Fiore F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96(8): 1166-1169. (Pubitemid 46625066)
19. Khambata-Ford S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25(22): 3230-3237. (Pubitemid 47325606)
20. De Roock W, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19(3): 508-515. (Pubitemid 351325672)
21. Allegra CJ, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27(12): 2091-2096.
22. Forbes SA, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010; 38 (Database issue): D652-657.
23. Loupakis F, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101(4): 715-721.
24. Lopez-Crapez E, et al. KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinicalnecessity? Br J Cancer 2010; 102(6): 1074-1075; author reply 1076-1077.
25. Smith G, et al. Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. Br J Cancer 2010; 102(4): 693-703.
26. Barbacid M. ras oncogenes: their role in neoplasia. Eur J Clin Invest 1990; 20(3): 225-235. (Pubitemid 20189316)
27. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892): 949-954. (Pubitemid 34716871)
28. Wan PT, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116(6): 855-867. (Pubitemid 38410730)
29. Wellbrock C, et al. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004; 5(11): 875-885. (Pubitemid 39486539)
30. Greer CE, et al. PCR ampliřcation from parafřn-embedded tissues. Effects of řxative and řxation time. Am J Clin Pathol 1991; 95(2): 117-124.
31. Monzon FA, et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009; 133(10): 1600-1606.
32. van Krieken JHJM, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Archiv 2008; 453: 417-431.
33. ČSN EN ISO 15189:2007 (85 5101) Zdravotnické laboratoře - Zvláštní požadavky na kvalitu a způsobilost.